Edition:
United States

Halozyme Therapeutics Inc (HALO.OQ)

HALO.OQ on NASDAQ Stock Exchange Global Select Market

11.56USD
2:21pm EST
Change (% chg)

$0.06 (+0.52%)
Prev Close
$11.50
Open
$11.50
Day's High
$12.03
Day's Low
$11.39
Volume
379,448
Avg. Vol
502,937
52-wk High
$14.38
52-wk Low
$6.96

HALO.OQ

Chart for HALO.OQ

About

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborat... (more)

Overall

Beta: 2.26
Market Cap(Mil.): $1,489.14
Shares Outstanding(Mil.): 129.49
Dividend: --
Yield (%): --

Financials

  HALO.OQ Industry Sector
P/E (TTM): -- 44.85 30.38
EPS (TTM): -0.56 -- --
ROI: -41.50 -1.38 14.86
ROE: -720.14 -1.07 16.28

BRIEF-Halozyme Therapeutics sees FY 2017 revenue $115 mln to $130 mln

* Halozyme Therapeutics-expects to report $20 million in 2016 revenue for reimbursed partner research and development expenses

Jan 09 2017

BRIEF-Halozyme sees FY 2017 revenue $115 mln to $130 mln

* Halozyme provides program updates, 2017 financial guidance at 35th annual JP Morgan healthcare conference

Jan 09 2017

Halozyme's pancreatic cancer drug succeeds in mid-stage trial

Halozyme Therapeutics Inc said its lead experimental drug, in tandem with therapies from Celgene Corp and Eli Lilly and Co, succeeded in a mid-stage study involving patients with an advanced form of pancreatic cancer.

Jan 05 2017

BRIEF-Halozyme reports Q3 loss per share $0.23

* Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S

Nov 07 2016

BRIEF-Halozyme reports second quarter 2016 financial results

* Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S

Aug 09 2016

BRIEF-Halozyme to resume enrollment in Phase 1B trial evaluating PEGPH20

* Resumed enrollment, dosing patients in phase 1B trial evaluating investigational new drug, PEGPH20, in combination with KEYTRUDA

Jul 25 2016

Competitors

  Price Chg
Novo Nordisk A/S (NOVOb.CO) kr.243.80 -5.00
Sanofi SA (SASY.PA) €74.84 -0.78
Eli Lilly and Co (LLY.N) $76.25 -0.56
Albireo Pharma Inc (ALBO.OQ) $18.76 -0.71
MannKind Corporation (MNKD.OQ) $0.69 +0.05

Earnings vs. Estimates